MTOR and skin basal cell carcinoma: Other mTORC1 inhibitors, such as rapamycin and its analogs, showed a better clinical response in cSCC than in BCC, probably due to the higher mTOR expression in SCC epidermal tissue (70, 75, 78, 120).